Science Applications Inte

Pro Medicus announces new CFO amid a steep year-to-date stock decline, with analysts split on its valuation. Meanwhile, U.S. markets extend weekly losses on Middle East tensions.

SELLAS Life Sciences (SLS) surged 6.3% to $11.19 as short interest climbed to 32.65% of float and trading volume doubled. The company amended executive severance terms and disclosed 78 of 80 events reached in its Phase 3 AML trial.

SELLAS Life Sciences (SLS) surged 12.6% to $10.33 on heavy volume after an 8-K filing revealed changes to executive severance terms. The stock's implied equity value reached $2.03 billion.

Artelo Biosciences shares plunged 10.5% to a 52-week low of $1.19 before rebounding to $2.01 in after-hours trading, driven by capital market moves and early-stage pipeline updates.

Jupiter Neurosciences shares fell 37% to $0.205 after announcing a $100M licensing deal for MDMA drug ALA-002 and a $2M stock offering, with trading volume exceeding 230 million shares.

Cellectar Biosciences secured up to $140 million in new funding and reported strong Phase 2b results for iopofosine, fueling plans for a confirmatory trial and FDA filing in Waldenström macroglobulinemia.

Sagimet Biosciences shares surged 38% after announcing a $175 million stock offering to fund a Phase 3 acne trial for denifanstat, with proceeds expected to support dermatology programs through 2028.

Firefly Neuroscience shares surged 126% following a massive expansion in its commercial brain-scan platform and a new AI initiative powered by NVIDIA hardware. The company reported a 33-fold increase in scan volumes to over 10,800 in 2025.